Why the study?
Conventional planar and visual semiquantitative radionuclide imaging for ATTR-CM have limitations, prompting validation of the quantitative Mayo 3D Score against myocardial pathology.
Does the quantitative Mayo 3D Score derived from 99mTc-pyrophosphate SPECT/CT improve diagnostic accuracy for ATTR-CM compared to conventional planar and visual semiquantitative approaches in patients with suspected ATTR-CM?
Observational (n=230)
Blinded readers
No
Does the quantitative Mayo 3D Score derived from 99mTc-pyrophosphate SPECT/CT improve diagnostic accuracy for ATTR-CM compared to conventional planar and visual semiquantitative approaches in patients with suspected ATTR-CM?
Effect estimate: AUROC 0.92 (95% CI 0.88-0.96)
Absolute Event Rate: 0.92% vs 0.87%
p-value: p=0.006
The quantitative Mayo 3D Score derived from 99mTc-pyrophosphate SPECT/CT provides excellent diagnostic accuracy for ATTR-CM, outperforming planar methods and correlating strongly with histologic amyloid burden.
May support quantitative SPECT/CT scoring for ATTR-CM diagnosis; hypothesis-generating pending prospective validation against planar methods.
BACKGROUND: Technetium-based cardiac amyloid radionuclide imaging enables noninvasive diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), but conventional planar and visual semiquantitative approaches have important limitations. We developed the quantitative 3-dimensional Mayo 3D Score, defined as the ratio of mean left ventricular myocardial radiotracer uptake to right atrial blood-pool uptake using computed tomography (CT)-fused single-photon emission CT (SPECT) volumes of interest, and sought to validate its diagnostic performance against myocardial pathology. METHODS: Consecutive patients who underwent 99m Tc-pyrophosphate SPECT/CT at Mayo Clinic for suspected ATTR-CM between June 2017 and January 2025 with archived myocardial tissue were included. Baseline characteristics, including demographics, echocardiogram, biomarkers, visual semiquantitative, and Mayo 3D Score metrics, were collected. Myocardial specimens underwent histopathologic confirmation of amyloid, with amyloid subtype determination and further semiquantitative grading of amyloid burden and deposition patterns. RESULTS: Among 230 patients (median age, 72 years; 78% male), 107 (47%) had ATTR-CM, of whom 9 had hereditary ATTR-CM. The Mayo 3D Score showed excellent discrimination against pathology (area under the receiver operating characteristic curve, 0.92 [0.88–0.96]), exceeding planar Perugini (0.87 [0.83–0.92]; P =0.006), and heart-to-contralateral lung ratio (0.86 [0.81–0.91]; P =0.004) and comparable to SPECT Perugini (0.90 [0.86–0.94]; P =0.12). A cutoff ≥1.0 yielded 86.0% sensitivity, 92.7% specificity, 91.1% positive predictive value, and 88.4% negative predictive value. Among ATTR-positive cases, the Mayo 3D Score correlated strongly with semiquantitative amyloid burden (Spearman ρ=0.69), was higher in pericellular than nodular deposition patterns ( P <0.001), and was not associated with vascular involvement ( P =0.42). CONCLUSIONS: In patients with suspected ATTR-CM undergoing 99m Tc-pyrophosphate SPECT/CT, the Mayo 3D Score demonstrated superior diagnostic performance compared with planar metrics and comparable to SPECT Perugini, while correlating with myocardial ATTR burden and deposition patterns on pathology. These findings support its integration as a quantitative adjunct within clinical diagnostic ATTR-CM workflows.
No takes yet. Share an insight, caveat, or question.
Tersalvi et al. (2026) conducted an observational in Suspected Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (n=230). Mayo 3D Score vs. Planar Perugini grading was evaluated on Diagnostic discrimination of ATTR-CM against pathology (AUROC) (AUROC 0.92, 95% CI 0.88-0.96, p=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: